Gilead Sciences (Foster City, CA) Launches An Educational Website On Advances In Combination Therapy For HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Dec. 6, 2005--Gilead Sciences, Inc. (Nasdaq:GILD) today announced the launch of, a new educational website featuring information about advances in HIV treatment -- also called Highly Active Antiretroviral Therapy or HAART -- for people living with HIV/AIDS. The site includes resources about recent changes and improvements in HIV treatment as well as advice and tools to help patients address a wide range of treatment issues. Its launch coincides with the ten year anniversary of the United States Food and Drug Administration's (FDA) approval of the first protease inhibitor and subsequent availability of HAART in the United States.

Back to news